MA38155B1 - Utilisation du pidotimod pour traiter le psoriasis - Google Patents
Utilisation du pidotimod pour traiter le psoriasisInfo
- Publication number
- MA38155B1 MA38155B1 MA38155A MA38155A MA38155B1 MA 38155 B1 MA38155 B1 MA 38155B1 MA 38155 A MA38155 A MA 38155A MA 38155 A MA38155 A MA 38155A MA 38155 B1 MA38155 B1 MA 38155B1
- Authority
- MA
- Morocco
- Prior art keywords
- pidotimod
- treat psoriasis
- psoriasis
- acceptable salt
- physiologically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention porte sur l'utilisation du pidotimod ou de son sel physiologiquement acceptable pour traiter le psoriasis. Dans l'invention, le pidotimod ou son sel physiologiquement acceptable peut être administré par voie systémique ou topique pour traiter le psoriasis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/076088 WO2014094840A1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter le psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38155A1 MA38155A1 (fr) | 2016-02-29 |
| MA38155B1 true MA38155B1 (fr) | 2016-09-30 |
Family
ID=47520054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38155A MA38155B1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter le psoriasis |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150328191A1 (fr) |
| EP (1) | EP2934521B1 (fr) |
| JP (1) | JP6051315B2 (fr) |
| KR (1) | KR20150095773A (fr) |
| CN (1) | CN104869994B (fr) |
| AR (1) | AR094027A1 (fr) |
| AU (1) | AU2012396942A1 (fr) |
| BR (1) | BR112015011391A2 (fr) |
| CA (1) | CA2887878A1 (fr) |
| CY (1) | CY1118645T1 (fr) |
| DK (1) | DK2934521T3 (fr) |
| EA (1) | EA201591185A1 (fr) |
| ES (1) | ES2617235T3 (fr) |
| HK (1) | HK1210937A1 (fr) |
| HR (1) | HRP20161666T1 (fr) |
| HU (1) | HUE031846T2 (fr) |
| IL (1) | IL239429A0 (fr) |
| LT (1) | LT2934521T (fr) |
| MA (1) | MA38155B1 (fr) |
| ME (1) | ME02560B (fr) |
| MX (1) | MX2015008104A (fr) |
| PH (1) | PH12015501210A1 (fr) |
| PL (1) | PL2934521T3 (fr) |
| PT (1) | PT2934521T (fr) |
| RS (1) | RS55436B1 (fr) |
| SG (1) | SG11201503270UA (fr) |
| SI (1) | SI2934521T1 (fr) |
| SM (1) | SMT201700072B (fr) |
| TN (1) | TN2015000142A1 (fr) |
| WO (1) | WO2014094840A1 (fr) |
| ZA (1) | ZA201502573B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (fr) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod à utiliser dans le traitement de maladies associées à une inflammation |
| US10765724B2 (en) | 2016-03-29 | 2020-09-08 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody |
| CN105943505A (zh) * | 2016-05-26 | 2016-09-21 | 杭州百诚医药科技股份有限公司 | 一种匹多莫德药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) * | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2003018011A1 (fr) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase |
-
2012
- 2012-12-19 AU AU2012396942A patent/AU2012396942A1/en not_active Abandoned
- 2012-12-19 PL PL12812221T patent/PL2934521T3/pl unknown
- 2012-12-19 MX MX2015008104A patent/MX2015008104A/es unknown
- 2012-12-19 WO PCT/EP2012/076088 patent/WO2014094840A1/fr active Application Filing
- 2012-12-19 SI SI201230870A patent/SI2934521T1/sl unknown
- 2012-12-19 US US14/652,482 patent/US20150328191A1/en not_active Abandoned
- 2012-12-19 SG SG11201503270UA patent/SG11201503270UA/en unknown
- 2012-12-19 LT LTEP12812221.5T patent/LT2934521T/lt unknown
- 2012-12-19 CA CA2887878A patent/CA2887878A1/fr not_active Abandoned
- 2012-12-19 EA EA201591185A patent/EA201591185A1/ru unknown
- 2012-12-19 BR BR112015011391A patent/BR112015011391A2/pt not_active IP Right Cessation
- 2012-12-19 ES ES12812221.5T patent/ES2617235T3/es active Active
- 2012-12-19 EP EP12812221.5A patent/EP2934521B1/fr active Active
- 2012-12-19 CN CN201280076628.9A patent/CN104869994B/zh active Active
- 2012-12-19 RS RS20161102A patent/RS55436B1/sr unknown
- 2012-12-19 PT PT128122215T patent/PT2934521T/pt unknown
- 2012-12-19 ME MEP-2016-277A patent/ME02560B/fr unknown
- 2012-12-19 HU HUE12812221A patent/HUE031846T2/hu unknown
- 2012-12-19 MA MA38155A patent/MA38155B1/fr unknown
- 2012-12-19 JP JP2015548221A patent/JP6051315B2/ja not_active Expired - Fee Related
- 2012-12-19 KR KR1020157018215A patent/KR20150095773A/ko not_active Application Discontinuation
- 2012-12-19 DK DK12812221.5T patent/DK2934521T3/en active
-
2013
- 2013-12-16 AR ARP130104757A patent/AR094027A1/es unknown
-
2015
- 2015-04-14 TN TNP2015000142A patent/TN2015000142A1/fr unknown
- 2015-04-16 ZA ZA2015/02573A patent/ZA201502573B/en unknown
- 2015-05-29 PH PH12015501210A patent/PH12015501210A1/en unknown
- 2015-06-15 IL IL239429A patent/IL239429A0/en unknown
- 2015-11-26 HK HK15111635.1A patent/HK1210937A1/xx unknown
-
2016
- 2016-12-07 HR HRP20161666TT patent/HRP20161666T1/hr unknown
-
2017
- 2017-01-30 SM SM201700072T patent/SMT201700072B/it unknown
- 2017-02-21 CY CY20171100232T patent/CY1118645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3397631T2 (ro) | 3-Azabiciclo[3.1.0] hexani substituiţi drept inhibitori de cetohexokinază | |
| EA201692271A1 (ru) | Терапевтически активные соединения и способы их применения | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| IN2015DN01156A (fr) | ||
| TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
| EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| IN2014DN09228A (fr) | ||
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| CL2012001293A1 (es) | Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| CA3010788A1 (fr) | Procedes d'administration de vasopresseurs | |
| MA38155A1 (fr) | Utilisation du pidotimod pour traiter le psoriasis | |
| MX2016007795A (es) | Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. | |
| MA38156B1 (fr) | Utilisation du pidotimod pour traiter la dermatite atopique | |
| FR2992219B1 (fr) | Composition pour le traitement de l'hypocalcemie chez les ruminants | |
| FR3005411B1 (fr) | Association d'actifs pour une administration par voie orale pour ameliorer la qualite des ongles. | |
| FR2976492B1 (fr) | Electrode combinee pour le traitement de l'hyperhidrose axillaire | |
| MA38455B1 (fr) | Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin | |
| TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
| FR2976493B1 (fr) | Electrode combinee pour le traitement de l'hyperhidrose | |
| MA38411B1 (fr) | Inhibiteurs de cdc7 | |
| MA38456B1 (fr) | Utilisation de pidotimode pour traiter le syndrome du côlon irritable | |
| MY177715A (en) | Use of pidotimod to treat atopic dermatitis |